nach oben

Erschienen in:

06.11.2020 | Ticagrelor

Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans

verfasst von: Margaret Infeld, Kevin A. Friede, Tan Ru San, Holly J. Knickerbocker, Geoffrey S. Ginsburg, Thomas L. Ortel, Deepak Voora

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Platelet gene polymorphisms are associated with variable on-treatment platelet reactivity and vary by race. Whether differences in platelet reactivity and aspirin or ticagrelor exist between African-American and European-Americans remains poorly understood. Biological samples from three prior prospective antiplatelet challenge studies at the Duke Clinical Research Unit were used to compare platelet reactivity between African-American and European-American subjects. Platelet reactivity at baseline, on-aspirin, on-ticagrelor, and the treatment effect of aspirin or ticagrelor were compared between groups using an adjusted mixed effects model. Compared with European-Americans (n = 282; 50% female; mean ± standard deviation age, 50 ± 16), African-Americans (n = 209; 67% female; age 48 ± 12) had lower baseline platelet reactivity with platelet function analyzer-100 (PFA-100) (p < 0.01) and with light transmission aggregometry (LTA) in response to arachidonic acid (AA), adenosine diphosphate (ADP), and epinephrine agonists (p < 0.05). African-Americans had lower platelet reactivity on aspirin in response to ADP, epinephrine, and collagen (p < 0.05) and on ticagrelor in response to AA, ADP, and collagen (p < 0.05). The treatment effect of aspirin was greater in European-Americans with an AA agonist (p = 0.002). Between-race differences with in vitro aspirin mirrored those seen in vivo. The treatment effect of ticagrelor was greater in European-Americans in response to ADP (p < 0.05) but with collagen, the treatment effect was greater for African-Americans (p < 0.05). Platelet reactivity was overall lower in African-Americans off-treatment, on aspirin, and on ticagrelor. European-Americans experienced greater platelet suppression on aspirin and on ticagrelor. The aspirin response difference in vivo and in vitro suggests a mechanism intrinsic to the platelet. Whether the absolute level of platelet reactivity or the degree of platelet suppression after treatment is more important for clinical outcomes is uncertain.

Nur mit Berechtigung zugänglich

Patrono C, Morais J, Baigent C et al (2017) Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol 70(14):1760–1776PubMedCrossRef

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2(8607):349–360

Antithrombotic TC (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRef

Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614–623PubMedCrossRef

Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961–965PubMedCrossRef

Wenaweser P, Dorffler-Melly J, Imboden K et al (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45(11):1748–1752PubMedCrossRef

Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167(15):1593–1599PubMedCrossRef

Cuisset T, Cayla G, Frere C et al (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5(3):325–329PubMedCrossRef

Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261–2273PubMedCrossRef

10.

Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36(27):1762–1771PubMedCrossRef

11.

Faraday N, Yanek LR, Mathias R et al (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490–2496PubMedCrossRef

12.

Frelinger AL 3rd, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25):2888–2896PubMedCrossRef

13.

Verdoia M, Sartori C, Pergolini P et al (2016) Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vasc Pharmacol 77:48–53CrossRef

14.

Siller-Matula JM, Akca B, Neunteufl T et al (2016) Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets 27(4):373–377PubMedCrossRef

15.

Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005) Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106(8):2723–2729PubMedPubMedCentralCrossRef

16.

Gaxiola B, Friedl W, Propping P (1984) Epinephrine-induced platelet aggregation. A twin study. Clin Genet 26(6):543–548PubMedCrossRef

17.

O’Donnell CJ, Larson MG, Feng D et al (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103(25):3051–3056PubMedCrossRef

18.

Bray PF, Mathias RA, Faraday N et al (2007) Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 5(8):1617–1623PubMedCrossRef

19.

Edelstein LC, Simon LM, Montoya RT et al (2013) Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 19(12):1609–1616PubMedPubMedCentralCrossRef

20.

Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF (1995) Gene frequencies of the five major human platelet antigens in African-American, white, and Korean populations. Transfusion 35(10):863–867PubMedCrossRef

21.

Ramsey G, Salamon DJ (1986) Frequency of PLA1 in blacks. Transfusion 26(6):531–532PubMedCrossRef

22.

Ulrich CM, Carlson CS, Sibert J et al (2005) Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 26(4):394–395PubMedCrossRef

23.

Weng Z, Li X, Li Y, Lin J, Peng F, Niu W (2013) The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS ONE 8(11):e78093PubMedPubMedCentralCrossRef

24.

Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057PubMedCrossRef

25.

Alexopoulos D, Xanthopoulou I, Gkizas V et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5(6):797–804PubMedCrossRef

26.

Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606PubMedCrossRef

27.

Ibrahim K, Christoph M, Schmeinck S et al (2014) High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 85(5):649–656PubMedCrossRef

28.

Vang JJ, Nilsson L, Berntsson P et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7(9):1556–1565CrossRef

29.

Wadowski PP, Eichelberger B, Kopp CW et al (2017) Disaggregation following agonist-induced platelet activation in patients on dual antiplatelet therapy. J Cardiovasc Transl Res 10(4):359–367PubMedPubMedCentralCrossRef

30.

Elwood PC, Cochrane AL, Burr ML et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1(5905):436–440PubMedPubMedCentralCrossRef

31.

The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336(8719):827–830CrossRef

32.

Ford ES (2013) Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardiol 61(22):2249–2252PubMedPubMedCentralCrossRef

33.

Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131(4):e29-322PubMed

34.

Albright KC, Huang L, Blackburn J et al (2018) Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality. Neurology 91(19):e1741–e1750PubMedPubMedCentralCrossRef

35.

Voora D, Ortel TL, Lucas JE et al (2012) Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis 33(3):246–257PubMedPubMedCentralCrossRef

36.

Ortel TL, James AH, Thames EH et al (2000) Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 84(1):93–97PubMed

37.

Valenti R, Cantini G, Marcucci R et al (2015) Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. Int J Cardiol 201:561–567PubMedCrossRef

38.

Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ (1985) Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 290(6466):428–432CrossRef

39.

Trip MD, Cats VM, van Capelle FJ, Vreeken J (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322(22):1549–1554PubMedCrossRef

40.

Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF (1991) Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84(2):613–617PubMedCrossRef

41.

Terres W, Lund GK, Hubner A, Ehlert A, Reuter H, Hamm CW (1995) Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Am Heart J 130(4):711–716PubMedCrossRef

42.

Elwood PC, Renaud S, Beswick AD, O’Brien JR, Sweetnam PM (1998) Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 80(6):578–582PubMedPubMedCentralCrossRef

43.

Meade TW, Cooper JA, Miller GJ (1997) Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 78(2):926–929PubMedCrossRef

44.

Gaglia MA Jr, Lipinski MJ, Lhermusier T et al (2017) Comparison of platelet reactivity in black versus white patients with acute coronary syndromes after treatment with ticagrelor. Am J Cardiol 119(8):1135–1140PubMedCrossRef

45.

Husted S, van Giezen JJ (2009) Ticagrelor: the first reversibly binding oral P2Y1P2Y12 receptor antagonist. Cardiovasc Ther 27(4):259–274PubMedCrossRef

46.

Zhao P, Metcalf M, Bunnett NW (2014) Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne) 5:67CrossRef

47.

Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M (2014) Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol 34(12):2644–2650PubMedPubMedCentralCrossRef

48.

Thomas KL, Honeycutt E, Shaw LK, Peterson ED (2010) Racial differences in long-term survival among patients with coronary artery disease. Am Heart J 160(4):744–751PubMedCrossRef

49.

Fernandez-Jimenez R, Wang TJ, Fuster V, Blot WJ (2019) Low-dose aspirin for primary prevention of cardiovascular disease: use patterns and impact across race and ethnicity in the southern community cohort study. J Am Heart Assoc 8(24):e013404PubMedPubMedCentralCrossRef

50.

Collins SD, Torguson R, Gaglia MA Jr et al (2010) Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 122(11):1085–1090PubMedCrossRef

51.

Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 140(3):240–261PubMedPubMedCentralCrossRef

52.

Casto AM, Feldman MW (2011) Genome-wide association study SNPs in the human genome diversity project populations: does selection affect unlinked SNPs with shared trait associations? PLoS Genet 7(1):e1001266PubMedPubMedCentralCrossRef

53.

Tourdot BE, Stoveken H, Trumbo D et al (2018) Genetic variant in human PAR (protease-activated receptor) 4 enhances thrombus formation resulting in resistance to antiplatelet therapeutics. Arterioscler Thromb Vasc Biol 38(7):1632–1643PubMedPubMedCentralCrossRef

54.

Edelstein LC, Simon LM, Lindsay CR et al (2014) Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 124(23):3450–3458PubMedPubMedCentralCrossRef

55.

Faraday N, Yanek LR, Yang XP et al (2011) Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118(12):3367–3375PubMedPubMedCentralCrossRef

56.

Qayyum R, Becker LC, Becker DM et al (2015) Genome-wide association study of platelet aggregation in African-Americans. BMC Genet 16:58PubMedPubMedCentralCrossRef

57.

Kambayashi J, Shinoki N, Nakamura T et al (1996) Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 81(1):85–90PubMedCrossRef

58.

Siffert W, Forster P, Jockel KH et al (1999) Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in European-American, Chinese, and Black African individuals. J Am Soc Nephrol 10(9):1921–1930PubMed

59.

Dusse F, Frey UH, Bilalic A et al (2012) The GNB3 C825T polymorphism influences platelet aggregation in human whole blood. Pharmacogenet Genom 22(1):43–49CrossRef

60.

Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF (2006) Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 4(9):2043–2050PubMedCrossRef

61.

Naber C, Hermann BL, Vietzke D et al (2000) Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Lett 484(3):199–201PubMedCrossRef

62.

Strisciuglio T, Franco D, Di Gioia G et al (2018) Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovasc Diagn Ther 8(5):610–620PubMedPubMedCentralCrossRef

63.

Morange PE, Simon C, Alessi MC et al (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109(11):1343–1348PubMedCrossRef

64.

Conlan MG, Folsom AR, Finch A et al (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70(3):380–385PubMedCrossRef

65.

Folsom AR, Aleksic N, Sanhueza A, Boerwinkle E (2009) Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample. Atherosclerosis 205(1):272–278PubMedCrossRef

66.

Lev EI, Bliden KP, Jeong YH et al (2014) Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 3(5):e001167PubMedPubMedCentralCrossRef

67.

Wilson JF, Weale ME, Smith AC et al (2001) Population genetic structure of variable drug response. Nat Genet 29(3):265–269PubMedCrossRef

68.

Rosenberg NA, Pritchard JK, Weber JL et al (2002) Genetic structure of human populations. Science 298(5602):2381–2385PubMedCrossRef

69.

Tang H, Quertermous T, Rodriguez B et al (2005) Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 76(2):268–275PubMedCrossRef

70.

Carson P, Ziesche S, Johnson G, Cohn JN (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5(3):178–187PubMedCrossRef

71.

Jamerson K, DeQuattro V (1996) The impact of ethnicity on response to antihypertensive therapy. Am J Med 101(3A):22S-32SPubMedCrossRef

72.

Ramamoorthy A, Pacanowski MA, Bull J, Zhang L (2015) Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 97(3):263–273PubMedCrossRef

73.

Teng R, Butler K (2014) Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and European-American volunteers. Int J Clin Pharmacol Ther 52(6):478–491PubMedCrossRef

Titel: Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans
verfasst von: Margaret Infeld
Kevin A. Friede
Tan Ru San
Holly J. Knickerbocker
Geoffrey S. Ginsburg
Thomas L. Ortel
Deepak Voora
Publikationsdatum: 06.11.2020
Verlag: Springer US
Schlagwörter: Ticagrelor
Collagen
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2021
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02327-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19

High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?

Increased intracranial hemorrhage of mechanical thrombectomy in acute ischemic stroke patients with atrial fibrillation

Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis

Expression of tissue factor mRNA in thrombosis associated with antiphospholipid syndrome